Canine Diabetic Ketoacidosis: Inpatient Decisions

Bottom line

Canine diabetic ketoacidosis (DKA) combines diabetic illness, ketosis, and acidosis. Fluids alone do not eliminate ketosis; insulin and appropriate electrolyte support are essential components of treatment. [1] Treat restoration of perfusion, suppression of ketogenesis, correction of treatment-related abnormalities, and recovery from concurrent disease as separate clinical tasks.

Establish the problem list before selecting the insulin protocol

Use a single admission worksheet to capture clinical status, glucose, beta-hydroxybutyrate (BHB), acid–base findings, electrolytes, renal findings, prior insulin exposure, and suspected precipitating disease. AAHA favors blood BHB over urinary acetoacetate for earlier, more accurate assessment. [1]

Distinguish observations from interpretations: record the actual assay and sample time, identify which results establish the working diagnosis, and state what remains unexplained. A diabetic dog with vomiting should not automatically be assigned DKA without assessing the metabolic evidence. Conversely, treatment already given before referral belongs beside the admission results, not only in the historical narrative.

A useful handover states the last insulin administration, all fluid and electrolyte inputs, the current monitoring plan, and the next decision. When abnormalities disagree with the bedside trajectory, reconcile sample timing, medication delivery, and the working diagnosis before simply escalating a protocol.

Match treatment intensity to monitoring capacity

AAHA recommends an appropriately staffed facility when the dog's clinical compromise or required monitoring exceeds the current practice's resources. Fluids and a potassium plan precede insulin; dextrose can be needed while insulin continues as glucose falls. [1]

Build the prescription around what can actually be measured and acted on. Assign responsibility for reviewing glucose and electrolytes, responding to a low result, and checking that prescribed treatment reached the patient. Specify a reassessment time after every meaningful change rather than leaving adjustments to the next routine ward round.

A protocol is a coordinated prescription, not merely a selected insulin concentration. Keep fluid inputs, additives, insulin delivery, nutrition, and sampling records together. During transfer, include trends and interventions between samples so the receiving team can interpret an apparent improvement or deterioration.

Read insulin comparisons by their actual endpoints

A randomized clinical trial compared fixed-rate with variable-rate intravenous regular insulin in dogs and cats. In the canine group, time to ketosis resolution did not differ; fixed-rate treatment was associated with shorter hospitalization, but survival to discharge did not differ. [2]

Importantly, all canine nonsurvivors in that trial had resolution of ketosis. [2] A favorable ketone endpoint therefore cannot stand in for survival, resolution of organ dysfunction, or readiness to discharge. Keep the dog-specific results separate from the cat results and avoid presenting one small trial as proof of a universally superior regimen.

When choosing between local protocols, record the reason for the choice and the monitoring resources it assumes. Compare the same outcomes when reviewing performance: biochemical recovery, complications, length of stay, and survival answer different questions. A shorter stay alone does not establish a safer protocol.

Place intramuscular lispro evidence in context

A small canine study compared prospectively treated intramuscular lispro cases with retrospectively included intravenous regular-insulin controls. Ketosis resolved sooner in the lispro group, but differences in acidemia resolution, ketoacidosis resolution, and hospitalization duration were not statistically significant. Recorded adverse-event frequency and severity did not differ. [3]

The comparison was not randomized and excluded dogs with venous pH below its severe-acidemia criterion and dogs with hyperglycemic hyperosmolar syndrome. [3] It supports a monitored alternative in selected patients, not removal of intensive monitoring or extrapolation to the excluded populations. Canine use of human insulin preparations requires attention to extra-label prescribing requirements in the relevant jurisdiction.

If considering an alternative route, review the complete published regimen with the clinical team rather than extracting an isolated dose. Document which patients resemble the studied population and which do not. Avoid borrowing only the favorable endpoint while omitting the study's eligibility restrictions and historical control design.

Investigate concurrent disease without losing metabolic surveillance

A retrospective referral cohort found concurrent disorders commonly, including pancreatitis, urinary infection, and hyperadrenocorticism. Electrolyte disturbances were also common. [4] These observations support an active concurrent-disease problem list, but do not establish that any particular diagnostic package or intervention causes better survival.

Use the canine acute pancreatitis management pathway when pancreatic disease remains a supported concurrent problem. Maintain diagnostic discipline when another endocrine disorder is considered: the hypoadrenocorticism testing pathway addresses the separate question of how to establish or exclude adrenal insufficiency.

Record why each additional investigation is being pursued, what a positive result would change, and whether it can wait until the patient is more stable. Revisit unresolved findings at handover; a falling BHB concentration should not close the rest of the case.

Make transition criteria explicit

AAHA bases transition toward maintenance insulin on improvement or resolution of BHB, hydration, and consistent eating; complete glycemic regulation before discharge is not the goal. [1]

Before discharge, reconcile the inpatient and home prescriptions, confirm the caregiver's ability to deliver the planned treatment, and document unresolved comorbidities and the follow-up task for each. The discharge summary should explain what has recovered, what remains under investigation, and what would prompt reassessment.

Frequently Asked Questions

Does hyperglycemia alone establish DKA?

No. The AAHA framework requires illness with ketosis and acidosis, rather than hyperglycemia alone. [1]

Why follow blood beta-hydroxybutyrate rather than only urine ketones?

AAHA identifies blood beta-hydroxybutyrate as an earlier and more accurate measure than urinary acetoacetate. [1]

Does a falling glucose concentration mean ketosis has resolved?

No. Fluids can lower glucose, but insulin is needed to eliminate ketosis; glucose and ketone endpoints must be assessed separately. [1]

Did fixed-rate insulin improve survival in the randomized trial?

No survival-to-discharge difference was detected between protocols in dogs. Ketosis resolved even in the dogs that did not survive to discharge. [2]

Was the intramuscular lispro comparison a randomized trial?

No. Prospectively treated lispro cases were compared with a retrospectively included regular-insulin control group. [3]

Does the lispro study establish superiority for every DKA patient?

No. Ketosis resolved sooner, but hospitalization duration did not differ significantly, and the study excluded dogs with very severe acidemia or hyperosmolar syndrome. [3]

Is pancreatitis the only concurrent disorder worth investigating?

No. The retrospective canine cohort also identified urinary infection and hyperadrenocorticism among common concurrent disorders. [4]